EPALINGES, Switzerland, Jan. 19, 2010 (GLOBE NEWSWIRE) -- Mymetics Corporation, a pioneer in the development of mucosal focused vaccines for human infectious diseases, announced today that following the vaccination of human volunteers as part of a clinical Phase I trial, the company’s first preventative HIV vaccine has been well tolerated.
